NEXTSTELLIS® revenue was US$14.1m vs US$4.2m in FY22 with sales momentum building. Dispensed cycles were up 2.5x July 2023 v July 2022 and up 80% in 2HFY23 vs 1HFY23 attributable to the positive impact of our refreshed leadership and marketing strategy.2 days agoMore than 3 fold revenue growth proves the company strategy success , with 75% reduction in marketing costs YOY , with the same rate , FY24 could reach 45 m to 50 Mil THEN so yes they are on the path to profitability . all indictors are positive .Share price outlook , if after the feb update that was 97 m worse the price reached 4.9 then after the +ve update expect 6 to 7 to 8.85 as per gauldman schs analysts
- Forums
- ASX - By Stock
- mayne market cap expected to grow to 1 b
MYX
mayne pharma group limited
Add to My Watchlist
0.10%
!
$5.01

NEXTSTELLIS® revenue was US$14.1m vs US$4.2m in FY22 with sales...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.01 |
Change
0.005(0.10%) |
Mkt cap ! $409.4M |
Open | High | Low | Value | Volume |
$5.05 | $5.09 | $4.96 | $227.6K | 45.27K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 250 | $4.99 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.02 | 194 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 16 | 4.990 |
3 | 1137 | 4.980 |
3 | 1573 | 4.970 |
2 | 734 | 4.960 |
3 | 2148 | 4.950 |
Price($) | Vol. | No. |
---|---|---|
5.020 | 194 | 6 |
5.030 | 75 | 1 |
5.040 | 551 | 2 |
5.050 | 125 | 1 |
5.060 | 734 | 2 |
Last trade - 11.40am 25/06/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |